334 related articles for article (PubMed ID: 26192479)
21. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
22. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
23. Aerosolized Medications for Gene and Peptide Therapy.
Laube BL
Respir Care; 2015 Jun; 60(6):806-21; discussion 821-4. PubMed ID: 26070576
[TBL] [Abstract][Full Text] [Related]
24. Hexanoic acid and polyethylene glycol double grafted amphiphilic chitosan for enhanced gene delivery: influence of hydrophobic and hydrophilic substitution degree.
Layek B; Haldar MK; Sharma G; Lipp L; Mallik S; Singh J
Mol Pharm; 2014 Mar; 11(3):982-94. PubMed ID: 24499512
[TBL] [Abstract][Full Text] [Related]
25. Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles.
Aissaoui A; Chami M; Hussein M; Miller AD
J Control Release; 2011 Sep; 154(3):275-84. PubMed ID: 21699935
[TBL] [Abstract][Full Text] [Related]
26. Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis.
Copreni E; Penzo M; Carrabino S; Conese M
Gene Ther; 2004 Oct; 11 Suppl 1():S67-75. PubMed ID: 15454960
[TBL] [Abstract][Full Text] [Related]
27. Role of small interfering RNA (siRNA) in targeting ocular neovascularization: A review.
Supe S; Upadhya A; Singh K
Exp Eye Res; 2021 Jan; 202():108329. PubMed ID: 33198953
[TBL] [Abstract][Full Text] [Related]
28. CpG-free plasmid expression cassettes for cystic fibrosis gene therapy.
Pringle IA; Hyde SC; Connolly MM; Lawton AE; Xu B; Nunez-Alonso G; Davies LA; Sumner-Jones SG; Gill DR
Biomaterials; 2012 Oct; 33(28):6833-42. PubMed ID: 22727465
[TBL] [Abstract][Full Text] [Related]
29. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting.
Kuang Y; An S; Guo Y; Huang S; Shao K; Liu Y; Li J; Ma H; Jiang C
Int J Pharm; 2013 Sep; 454(1):11-20. PubMed ID: 23867728
[TBL] [Abstract][Full Text] [Related]
30. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.
Ferrari S; Geddes DM; Alton EW
Adv Drug Deliv Rev; 2002 Dec; 54(11):1373-93. PubMed ID: 12458150
[TBL] [Abstract][Full Text] [Related]
31. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung.
Yei S; Mittereder N; Wert S; Whitsett JA; Wilmott RW; Trapnell BC
Hum Gene Ther; 1994 Jun; 5(6):731-44. PubMed ID: 7948135
[TBL] [Abstract][Full Text] [Related]
32. The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium.
Kitson C; Angel B; Judd D; Rothery S; Severs NJ; Dewar A; Huang L; Wadsworth SC; Cheng SH; Geddes DM; Alton EW
Gene Ther; 1999 Apr; 6(4):534-46. PubMed ID: 10476213
[TBL] [Abstract][Full Text] [Related]
33. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution.
O'Mahony AM; Godinho BM; Cryan JF; O'Driscoll CM
J Pharm Sci; 2013 Oct; 102(10):3469-84. PubMed ID: 23893329
[TBL] [Abstract][Full Text] [Related]
34. Gene therapy for the respiratory manifestations of cystic fibrosis.
Korst RJ; McElvaney NG; Chu CS; Rosenfeld MA; Mastrangeli A; Hay J; Brody SL; Eissa NT; Danel C; Jaffe HA
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S75-87. PubMed ID: 7533609
[TBL] [Abstract][Full Text] [Related]
35. A new era of targeting cystic fibrosis with non-viral delivery of genomic medicines.
Turuvekere Vittala Murthy N; Vlasova K; Renner J; Jozic A; Sahay G
Adv Drug Deliv Rev; 2024 Jun; 209():115305. PubMed ID: 38626860
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy for cystic fibrosis by means of aerosol.
Rochat T; Morris MA
J Aerosol Med; 2002; 15(2):229-35. PubMed ID: 12184873
[TBL] [Abstract][Full Text] [Related]
37. Novel therapies for the treatment of cystic fibrosis: new developments in gene and stem cell therapy.
Sueblinvong V; Suratt BT; Weiss DJ
Clin Chest Med; 2007 Jun; 28(2):361-79. PubMed ID: 17467554
[TBL] [Abstract][Full Text] [Related]
38. Inhaled gene therapy of preclinical muco-obstructive lung diseases by nanoparticles capable of breaching the airway mucus barrier.
Kim N; Kwak G; Rodriguez J; Livraghi-Butrico A; Zuo X; Simon V; Han E; Shenoy SK; Pandey N; Mazur M; Birket SE; Kim A; Rowe SM; Boucher R; Hanes J; Suk JS
Thorax; 2022 Aug; 77(8):812-820. PubMed ID: 34697091
[TBL] [Abstract][Full Text] [Related]
39. A novel PEGylation of chitosan nanoparticles for gene delivery.
Zhang Y; Chen J; Zhang Y; Pan Y; Zhao J; Ren L; Liao M; Hu Z; Kong L; Wang J
Biotechnol Appl Biochem; 2007 Apr; 46(Pt 4):197-204. PubMed ID: 17147512
[TBL] [Abstract][Full Text] [Related]
40. Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.
Manunta MD; McAnulty RJ; Tagalakis AD; Bottoms SE; Campbell F; Hailes HC; Tabor AB; Laurent GJ; O'Callaghan C; Hart SL
PLoS One; 2011; 6(10):e26768. PubMed ID: 22046351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
